|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The substantial acute reduction of lipoprotein (a) (means: 65%, heterozygous FH; 68%, homozygous FH) has not been reported with other therapies.
|
1414897 |
1992 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Detection of the Pro664-Leu mutation in the low-density lipoprotein receptor and its relation to lipoprotein(a) levels in patients with familial hypercholesterolemia of Dutch ancestry from The Netherlands and Canada.
|
1493640 |
1992 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Relationship between apolipoprotein(a) phenotype, lipoprotein(a) concentration in plasma, and low density lipoprotein receptor function in a large kindred with familial hypercholesterolemia due to the pro664----leu mutation in the LDL receptor gene.
|
1830890 |
1991 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Diverse effect of ethnicity on plasma lipoprotein[a] levels in heterozygote patients with familial hypercholesterolemia.
|
1836489 |
1991 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Segregation analysis of plasma lipoprotein(a) levels in pedigrees with molecularly defined familial hypercholesterolemia.
|
7607414 |
1995 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of lipoprotein (a) in children with familial hypercholesterolemia.
|
8197753 |
1994 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An investigation of the influence of selected factors on the clinical expression of the FH Afrikaner-1 mutation in this family indicated that it was especially the elevated apolipoprotein (a) levels, in addition to low levels of high density lipoprotein cholesterol and raised triglyceride and apolipoprotein B levels, that were associated with a greater risk of developing CHD.
|
8370148 |
1993 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein (a) [apo(a)] phenotype was determined in 112 of FH and non-FH subjects.
|
8548413 |
1996 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The possible influence of apo E polymorphism on components of variation in plasma LDL-C, triglycerides, high-density lipoprotein cholesterol (HDL-C), and lipoprotein(a) (Lp(a)) levels was investigated in 235 members of 14 families with FH.
|
8722744 |
1996 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The short-term effects of low-density lipoprotein (LDL) apheresis using a dextran sulfate-cellulose (DSC) column equipped with a plasma separator using a polysulfone (PS) membrane filter on the serum total cholesterol, lipoprotein(a) (Lp(a)), C4b binding protein (C4bp), protein C and protein S and complement components levels were examined in a patient with familial hypercholesterolemia (heterozygote, type IIa).
|
9222877 |
1994 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study's aim was to determine whether biochemical risk factors such as lipoprotein(a), fibrinogen, homocysteine, and insulin, as well as low-density lipoprotein (LDL) particle size, were predictive of carotid intimamedia thickness (IMT), an early marker of atherosclerosis, in subjects with familial hypercholesterolemia (FH).
|
10235090 |
1999 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Total cholesterol and lipoprotein (a) were increased in FH children compared to controls (282.3+/-8.8 mg/dl vs. 163.8+/-4.6 mg/dl and 11.0[4.6, 30.7]mg/dl vs. 5.24[2.63, 11.0]mg/dl median [IQR] respectively; p<0.001 for both).
|
19004443 |
2009 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phenotypic diversity of familial hypercholesterolemia (FH) and lipoprotein(a) hyperlipidemia (Lp(a)-HLP), as defined risks for coronary artery disease with genetic background, and their frequent co-incidence with additional cardiovascular risk factors require a critical revisiting of the current diagnostic and screening criteria as well as therapeutic recommendations established for FH or isolated Lp(a)-HLP, since there is no clear guidance for patient stratification and disease management for combined cases.
|
20129380 |
2009 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation.
|
24632281 |
2014 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase 2 and 3 clinical trials in patients with moderate and severe hypercholesterolemia (including FH) show that this approach is safe and highly efficacious to lower LDL-C and lipoprotein(a).
|
25248569 |
2014 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] increases CAD in FH, although the independence of this association relative to other CAD risk factors remains unclear.
|
26340131 |
2015 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess the relationship between LDLR genotype and the plasma levels of PCSK9, LDL-C, and lipoprotein (a) (Lp(a)) in a large cohort of genetically defined FH heterozygotes (HeFH).
|
26371983 |
2015 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
|
26632531 |
2016 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
|
27594539 |
2016 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to investigate the associations of lipoprotein (a) [Lp(a)] with the FH phenotype, genotype and roles of Lp(a) in determining CAD risk among patients with and without FH.
|
28351002 |
2017 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increasing attention has come upon the genetic disorders of familial hypercholesterolemia and elevated lipoprotein(a).
|
28429242 |
2017 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia.
|
28502508 |
2018 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study confirmed that the MFHS is a strong predictor of prevalent CVD in FH and that the addition of lipoprotein(a) offers a minor improvement in the discrimination of the score.
|
28801029 |
2018 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
to analyze the relationship between lipid disturbance, including lipoprotein(a) (Lp(a)) levels, and development of ischemic heart disease (IHD) in patients with familial hypercholesterolemia (FH).
|
29096862 |
2017 |
|
Hyperlipoproteinemia Type IIa
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent literature involving CNVs and dyslipidemias has focused mainly on rare CNVs causing familial hypercholesterolemia, and a common CNV polymorphism as the major determinant of lipoprotein(a) plasma concentrations.
|
29303791 |
2018 |